Columns

(Photo from James Pollard, Personal Collection) The above New York Times clipping, dated March 24, 1993, reports breaking news that was immensely important for the Huntington’s disease community. Even today, 26 years later, the significance of a piece of HD news has never surpassed this. Not yet anyway. The…

I imagine some of you know people who are experts at worrying. Pick any situation and these worrywarts will rev up with a highlight reel of catastrophic scenarios usually involving pain, blood, and a depressing outcome. For the record, I’m the opposite of that kind of person. I fall into…

Sometimes when you meet a person, there’s an immediate connection. Like kindred spirits, you become instant friends. When I attended my first Huntington Society of Canada National Conference, I met someone like that, and my mind opened to a new way of thinking. At the time, I was still…

When I was a child, my mother would tell me that if I didn’t eat my carrots, I would go blind. I do wear glasses now, so maybe that was partially correct. But it’s more likely that she was either misinformed or just trying to get me to eat my…

Exercise and physical activity may benefit patients with Huntington’s disease (HD), a new review study shows. The study, “Physical Therapy and Exercise Interventions in Huntington’s Disease: A Mixed Methods Systematic Review,” appeared in the Journal of Huntington’s Disease. Significant research shows that exercise and physical therapy improve the…

This week marks the launch of the “7,000 Mile Rare Movement,” a nationwide effort to raise money for research into the 7,000 known rare diseases that afflict at least 30 million Americans. The campaign kicks off Feb. 1 and culminates with Rare Disease Day on Feb. 28. Organized by…

Neurofeedback training may increase brain connectivity in patients with Huntington’s disease, possibly improving behavior and movement abnormalities, say British researchers at University College London. Their study, “Stimulating neural plasticity with real-time fMRI neurofeedback in Huntington’s disease: A proof of concept study,” appeared in the journal Human Brain Mapping.

The European Medicines Agency (EMA) has granted orphan medicinal product designation to AMT-130, uniQure’s gene therapy candidate for the treatment of Huntington’s disease. AMT-130 is an experimental gene therapy that is being evaluated in studies designed to support an investigational new drug (IND) application with the U.S.

uniQure expects to advance the clinical development of its Huntington’s disease investigational gene therapy, called AMT-130, during 2018. The company says it plans to file an investigational new drug application (IND) with the U.S. Food and Drug Administration (FDA) in the second half of 2018. The first human clinical trial…

Keeping a strict eating schedule may help improve the quality of life of patients with Huntington’s disease and other neurodegenerative disorders, a mouse study suggests. The study, “Time restricted feeding improves circadian dysfunction as well as motor symptoms in the Q175 mouse model of Huntington’s disease,” appeared…